Organization Overview
Historical Acquisition Tree
Alternative names
dinutuximab (unituxin) (2015 NDA)
treprostinil (remodulin) (2002 NDA)
Key: United Therapeutics (5) Acquired (4)
Acute Lung Injury (Phase 2)
Anemia, Sickle Cell (Phase 3)
Bronchopulmonary Dysplasia (Phase 1)
Calcinosis (Phase 2)
Cardiovascular Diseases (Phase 3)
Connective Tissue Diseases (Phase 4)
Delayed Graft Function (Phase 2)
Emphysema (Phase 3)
Familial Primary Pulmonary Hypertension (Phase 4)
Fibrosis (Phase 3)
Foot Ulcer (Phase 3)
Heart Failure (Phase 3)
Hepatitis (Phase 2)
Hepatitis A (Phase 2)
Hepatitis C (Phase 2)
Hypertension (Phase 4)
Hypertension, Pulmonary (Phase 4)
Idiopathic Pulmonary Fibrosis (Phase 3)
Ischemia (Phase 3)
Lung Diseases (Phase 3)
Lung Diseases, Interstitial (Phase 3)
Lung Diseases, Obstructive (Phase 3)
Lung Neoplasms (Phase 3)
Neuroblastoma (Phase 2)
Peripheral Arterial Disease (Phase 3)
Peripheral Vascular Diseases (Phase 3)
Persistent Fetal Circulation Syndrome (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 3)
Pulmonary Fibrosis (Phase 3)
Raynaud Disease (Phase 1)
Renal Insufficiency (Phase 1)
Reperfusion Injury (Phase 2)
Respiratory Distress Syndrome (Phase 2)
Respiratory Distress Syndrome, Newborn (Phase 2)
Respiratory Tract Diseases (Phase 3)
Sarcoidosis (Phase 3)
Scleroderma, Diffuse (Phase 4)
Scleroderma, Localized (Phase 2)
Scleroderma, Systemic (Phase 4)
Sclerosis (Phase 4)
Small Cell Lung Carcinoma (Phase 3)
Vascular Diseases (Phase 3)
Wounds and Injuries (Phase 2)